The Needle-Free Drug Delivery Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts

Release Date: October 2015
Number of Pages: 157
Number of Tables and Figures: 49

Synopsis: Hypodermic needle-based Injections continue to be the primary option for the delivering large molecule drugs which would break down in the gastrointestinal tract if consumed orally. Despite their common use, needles have several drawbacks including but not limited to needle stick injuries, patient non-compliance and needle phobia. Furthermore, needles can be a source of disease transmission, particularly when they are re-used and used incorrectly.

To address these shortcomings, a number of needle-free drug delivery platforms have emerged. Among the potential alternatives are needle-free injections, transdermal patches, microneedles, nasal sprays and inhalers. Significant R&D investments are also being made in the oral delivery of large molecules.

Needle-free drug delivery platforms promise to make the administration of injectable drugs more efficient and less painful. Despite challenges relating to manufacturing, formulation complexities and regulation, SNS Research estimates that needle-free drug delivery will grow to a $5 Billion market by the end of 2020.

The “Needle-Free Drug Delivery Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the needle-free drug delivery ecosystem including delivery technologies, key trends, market drivers, challenges, application areas, regulatory landscape, leading products, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for needle-free drug delivery from 2015 through to 2030. The forecasts are segmented for 5 delivery platforms, 5 application areas, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.



For a sample of the report or any further inquiries please contact info@snstelecom.com

Pricing: The report is available for the following price: 

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500


Key Findings:
The report has the following key findings:
  • Despite challenges relating to manufacturing, formulation complexities and regulation, SNS Research estimates that needle-free drug delivery will grow to a $5 Billion market by the end of 2020.
  • In terms of delivery platform categorization, we expect that needle-free injections will continue to dominate the market with an estimated market share of 33% in 2020.
  • Significant R&D investments are also being made in the oral delivery of large molecules. For example, Novartis is currently evaluating the delivery of selected proprietary biologics with a smart pill platform developed by Rani Therapeutics.
  • In the fast growing generic drugs market, pharmaceutical companies are increasingly keen to differentiate their products with needle-free technologies.

Topics Covered:
The report covers the following topics:
  • Needle-free drug delivery ecosystem
  • Market drivers and barriers
  • Technology, economics and key trends
  • Analysis of key application areas
  • Needle-free injections, nasal, pulmonary, transdermal and oral drug delivery platforms
  • Advanced needle-based drug delivery platforms
  • Active and passive drug delivery mechanisms
  • Regulatory landscape of needle-free drug delivery throughout the globe
  • Industry roadmap and value chain
  • Profiles and strategies of over 70 leading ecosystem players
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2015 till 2030

Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Delivery Platform
    • Needle-Free Injections
    • Nasal & Pulmonary Delivery
    • Transdermal Delivery
    • Advanced Needle-Based Platforms
    • Oral & Other Delivery Platforms
  • Application Area
    • Diabetes
    • Pediatrics
    • Pain Relief
    • Vaccination
    • Other Applications
  • Regional Markets
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the needle-free drug delivery opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2020 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • How big is the market for advanced needle-based drug delivery platforms?
  • How does regulation impact the adoption of needle-free drug delivery platforms?
  • Who are the key market players and what are their strategies?
  • How will the growing adoption of generic drugs impact the market?
  • What are the future prospects of oral platforms for delivering injectable drugs?
  • What strategies should needle-free platform providers and drug manufacturers adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:

3M
Actavis
Activa Brand Products
Adapt Pharma
AirXpanders
Akra Dermojet
Altran Group
Antares Pharma
ANVISA (Brazilian Health Surveillance Agency)
AstraZeneca
Battelle (Battelle Memorial Institute)
Baxter
BD (Becton, Dickinson and Company)
Bespak
bioCSL
Bioject Medical Technologies
Cambridge Consultants
CareFusion
Catalent
CDSCO (Central Drugs Standard Control Organization, India)
CFDA (China Food and Drug Administration)
COFEPRIS (Federal Commission for the Protection against Sanitary Risks, Mexico)
Consort Medical
Corium International
Crossject
CSL Group
DCI (D’Antonio Consultants International)
Debiotech
Echo Therapeutics
EDA (Egyptian Drug Authority)
EMA (European Medicines Agency)
Endo International
EPG (European Pharma Group)
Eternity Healthcare
Ferring Pharmaceuticals
Glide Technologies
GSK (GlaxoSmithKline)
Health Canada
Ichor Medical Systems
ICURE Pharmaceutical
Impel NeuroPharma
InCube Labs
Injex UK
Israeli MoH (Ministry of Health)
ITI (Immunomic Therapeutics, Inc.)
Janssen Pharmaceutical Companies
Johnson & Johnson
Keystone Industries
MannKind Corporation
Marathon Pharmaceuticals
MCC (Medicines Control Council, South Africa)
MedImmune
Merck and Co.
Merck KGaA
Merck Serono
MFDS (Ministry of Food and Drug Safety, South Korea)
MHLW (Ministry for Health Labor and Welfare, Japan)
Ministry of Health and Family Welfare, India
MIT (Massachusetts Institute of Technology)
MIT (Medical International Technologies)
Mundipharma
nanoBioSciences
National Medical Products
Nemaura Pharma
Novartis
P&G (Procter & Gamble)
Par Pharmaceutical Companies
Penjet Corporation
Pfizer
PharmaJet
PharmBioTec
PKA SoftTouch Corporation
PMDA (Pharmaceuticals and Medical Devices Agency, Japan)
Portal Instruments
Prometheon Pharma
Rani Therapeutics
Rhenovia Pharma
Russian MoH (Ministry of Healthcare)
Saarland University
Sanofi
Seagull Technologies
SFDA (Saudi Food and Drug Authority)
Smiths Medical
SymBio Pharmaceuticals
Teva Pharmaceutical Industries
The Medicines Company
TheraJect
TSI (Transdermal Specialties, Inc.)
Tyndall National Institute
U.S. FDA (Food and Drug Administration)
Unilife Corporation
Valeritas
Vaxxas
WHO (World Health Organization)
Ypsomed
Zogenix
Zosano Pharma Corporation
Zynerba Pharmaceuticals


Comments